Mast cell–expressed Mrgprb2/MRGPRX2 mediates gout pain and inflammation via a neuroimmune axis
JCI Insight · 23.01.2026 · 11 (2)
DOI: 10.1172/jci.insight.201781 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 23.01.2026. Verfasst von Lin Yang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Anesthesiology and Pain Research Institute, Second Affiliated Hospital. Hauptthemen laut MEDLINE: Mast Cells, Receptors, G-Protein-Coupled, Nerve Tissue Proteins, Receptors, Neuropeptide. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China, the Key Project of Hunan Province Natural Science Funds, the Key R&D Program of Hunan Province Natural Science Funds.
Abstract (Originalsprache)
Acute severe joint pain is a major symptom in gouty arthritis (GA), and its adequate treatment represents an unmet medical need. Mrgprb2, a specific mast cell receptor, has been implicated in the generation of chronic pain by mobilizing mast cell degranulation, yet its significance in GA pain and joint inflammation is still not well defined. Here, we found that Mrgprb2 was expressed in mouse synovial mast cells. In a murine model of GA, acute blockade or genetic deletion of Mrgprb2 significantly attenuated arthritis pain and hyperexcitability of joint nociceptors with significant reductions in innate immune cell recruitment in the synovium. Under naive conditions, activation of synovial Mrgprb2 was sufficient to excite peripheral terminals of joint nociceptors to induce acute joint hypernociception via the mobilization of mast cell degranulation. Additionally, the level of the neuropeptide substance P (SP) was elevated in the synovium of GA model mice. Using humanized MRGPRX2-knockin mice, we revealed that SP contributed to joint pain and inflammation by activating mast cells through Mrgprb2/MRGPRX2. These findings suggest that synovial mast cell–expressed Mrgprb2/MRGPRX2 merits consideration as a key neuroimmune player and a potential therapeutic target for treating GA pain and joint inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anesthesiology and Pain Research Institute, Second Affiliated Hospital.
- Hengyang Medical School.
- Department of Anesthesiology, Second Affiliated Hospital.
- Department of Anesthesiology, First Affiliated Hospital, and.
- Department of Endocrinology, Second Affiliated Hospital, University of South China, Hengyang, Hunan, China.
- College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Förderung
- Natural Science Foundation of China
- the Key Project of Hunan Province Natural Science Funds
- the Key R&D Program of Hunan Province Natural Science Funds
- Hunan Clinical Research Center for Acute and Chronic Pain
- Hunan Clinical Research Center for Obesity Related Diseases
Zitieren
APA
Yang, L., Liu, C., Xiao, J., Song, Y., Chen, H., Li, D., Zou, C., Hong, T., Liu, Y., Qi, D., Limjunyawong, N., Liu, W., & Qu, L. (2026). Mast cell–expressed Mrgprb2/MRGPRX2 mediates gout pain and inflammation via a neuroimmune axis. JCI Insight, 11(2). https://doi.org/10.1172/jci.insight.201781
Vancouver
Yang L, Liu C, Xiao J, Song Y, Chen H, Li D, et al. Mast cell–expressed Mrgprb2/MRGPRX2 mediates gout pain and inflammation via a neuroimmune axis. JCI Insight. 2026;11(2). doi:10.1172/jci.insight.201781
BibTeX
@article{Yang2026,
author = {Yang, Lin and Liu, Chengxi and Xiao, Jin and Song, Yu and Chen, Huan and Li, Dan and Zou, Cong and Hong, Tao and Liu, Yinglan and Qi, Dake and Limjunyawong, Nathachit and Liu, Wenjie and Qu, Lintao},
title = {Mast cell–expressed Mrgprb2/MRGPRX2 mediates gout pain and inflammation via a neuroimmune axis},
journal = {JCI Insight},
year = {2026},
volume = {11},
number = {2},
doi = {10.1172/jci.insight.201781}
}
EUVIMED